Welcome to a laptop battery specialist of the Apple Ac Adapter
HCA Holdings Inc. (HCA, $32.20, +$0.45, +1.42%), the largest private-sector hospital operator in the U.S., declared a special cash dividend of $2 a share which will be funded by a $1 billion offering of nine-year senior notes. HCA previously had announced special payouts of a $2 a share in February and $2.50 a share in October, which puts the year's special-dividend payments at $3 billion.
Deustche Bank upgraded shares of slot-machine maker International Game Technology (IGT, $14.24, +$0.37, +2.67%) to buy and raised its price target to $19 from $16, saying in a note to clients that it sees "little downside risk in the least expensive, most liquid, equipment supplier, in an environment where replacement demand isn't shrinking and numbers are beatable and likely going higher."
MGIC Investment Corp. (MTG, $1.89, +$0.14, +8.00%) disclosed late Friday that it had won approval from Freddie Mac (FMCC) to sell coverage out of a new subsidiary. MGIC management always had made the approval seem like it was all but certain, but the stock with battery such as Apple A1021 Ac Adapter, Apple ACD55 Ac Adapter, Apple M4402 Ac Adapter, Apple M4896 Ac Adapter, Apple M5937 Ac Adapter, Apple M7332 Ac Adapter, Apple M8482 Ac Adapter, Apple iBook G4 14 inch Ac Adapter, Apple iBook G4 14.1 inch M9165LL/A Ac Adapter, Apple PowerBook G4 1.33GHz 12.1-inch DVI FW800 M9184LL/A Ac Adapter, Apple PowerBook G4 1.33GHz 17-inch DVI WideScreen FW800 M9110LL/A Ac Adapter, Apple PowerBook G4 12.1-inch M8760S/A Ac Adapter reaction shows investors weren't so sure. The agreement with Freddie involves two separate matters: an agreement by MGIC to pay $267.5 million to Freddie to resolve a dispute over previous insurance claims, and the resolution of an unrelated impasse between Freddie and MGIC's primary regulator in Wisconsin.
After Myriad Genetics Inc.'s (MYGN, $27.73, -$0.99, -3.45%) stock briefly touched its old $31 price target last month, Mizuho downgraded Myriad Genetics to neutral and trimmed $1 off its target. "We are concerned that the stock may languish while the US Supreme Court again hears upon whether isolated human genes can be patented." Oral arguments are expected in March and a final decision then wouldn't be likely before midyear. There is "no near-term catalyst to counter the pressure from patent uncertainty," the firm said.
Goldman Sachs cut QLogic Corp. (QLGC, $8.75, -$0.73, -7.70%) and fellow networking name Emulex Corp. (ELX, $6.97, -$0.39, -5.24%) to sell from neutral, saying the companies face "long-term secular headwinds pertaining to their core fibre channel adapter businesses, along with heightened near-term cyclical risk from the server market and host-bus-adapter-to-server attach rates." The firm put its 12-month price target for QLogic and Emulex at $8 and $6, respectively.